EPIVIR-HBV
LOE ApproachingNDAORALSOLUTIONPriority Review
Approved
Dec 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EPIVIR-HBV is an oral small-molecule antiviral solution approved by GSK in 1998 for the treatment of hepatitis B virus (HBV) infection. The drug belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class, though its specific mechanism of action data is not detailed in available records. It is administered orally as a liquid formulation.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30%), indicating a defensive commercial posture and potential downsizing or transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on EPIVIR-HBV offers limited growth potential and career advancement opportunities given its LOE-approaching status and minimal linked job openings. Roles tend to focus on defending market share and managing decline rather than driving innovation or expansion.
Brand ManagerProduct Manager
Worked on EPIVIR-HBV at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.